3,443 Shares in AstraZeneca PLC (NASDAQ:AZN) Acquired by Blueshift Asset Management LLC

Blueshift Asset Management LLC bought a new stake in AstraZeneca PLC (NASDAQ:AZN) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 3,443 shares of the company’s stock, valued at approximately $268,000.

Several other hedge funds also recently bought and sold shares of AZN. WorthPointe LLC acquired a new stake in shares of AstraZeneca during the third quarter worth about $214,000. Glenmede Trust Co. NA raised its holdings in AstraZeneca by 3.7% during the 3rd quarter. Glenmede Trust Co. NA now owns 191,132 shares of the company’s stock worth $14,891,000 after buying an additional 6,808 shares during the period. Hardy Reed LLC lifted its stake in AstraZeneca by 5.9% in the third quarter. Hardy Reed LLC now owns 3,182 shares of the company’s stock valued at $248,000 after buying an additional 178 shares in the last quarter. Townsquare Capital LLC boosted its holdings in shares of AstraZeneca by 55.9% in the third quarter. Townsquare Capital LLC now owns 86,369 shares of the company’s stock valued at $6,729,000 after buying an additional 30,953 shares during the period. Finally, Principal Street Partners LLC increased its position in shares of AstraZeneca by 98.2% during the third quarter. Principal Street Partners LLC now owns 18,134 shares of the company’s stock worth $1,414,000 after acquiring an additional 8,986 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

NASDAQ AZN opened at $67.20 on Friday. The firm has a market capitalization of $208.36 billion, a P/E ratio of 32.15, a price-to-earnings-growth ratio of 1.23 and a beta of 0.47. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The firm’s fifty day moving average price is $72.48 and its two-hundred day moving average price is $77.50. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same period in the prior year, the firm earned $0.87 EPS. AstraZeneca’s quarterly revenue was up 18.0% compared to the same quarter last year. As a group, research analysts anticipate that AstraZeneca PLC will post 4.1 EPS for the current year.

Wall Street Analyst Weigh In

AZN has been the subject of a number of research analyst reports. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. TD Cowen lifted their target price on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Erste Group Bank raised AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Three investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.